Comgest Growth Europe EUR X AccRegister to Unlock Ratings |
Performance History | 31/03/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | - | 22.0 | 10.7 | |
+/-Cat | - | - | - | 8.6 | 3.6 | |
+/-B’mrk | - | - | - | 8.5 | 2.2 | |
Category: Europe Large-Cap Growth Equity | ||||||
Category Benchmark: Morningstar DM Europe Grt T... |
Key Stats | ||
NAV 30/04/2024 | EUR 12.66 | |
Day Change | -1.07% | |
Morningstar Category™ | Europe Large-Cap Growth Equity | |
ISIN | IE00BYYLPF67 | |
Fund Size (Mil) 30/04/2024 | EUR 6245.80 | |
Share Class Size (Mil) 30/04/2024 | EUR 65.08 | |
Max Initial Charge | - | |
Ongoing Charge 20/02/2023 | 0.05% |
Investment Objective: Comgest Growth Europe EUR X Acc |
The investment objective of the Fund is to create a professionally managed portfolio consisting of what, in the opinion of the Investment Manager, are high quality long-term growth companies having their headquarters or carrying out their predominant activities in Europe. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Franz Weis 01/11/2009 | ||
Pierre Lamelin 28/02/2022 | ||
Click here to see others | ||
Inception Date 25/04/2022 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR EUR | Morningstar DM Europe Grt TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Comgest Growth Europe EUR X Acc | 31/01/2024 |
|
|
Top 5 Holdings | Sector | % |
ASML Holding NV | Technology | 8.88 |
Novo Nordisk A/S Class B | Healthcare | 8.48 |
Accenture PLC Class A | Technology | 4.80 |
Essilorluxottica | Healthcare | 4.60 |
Experian PLC | Industrials | 4.18 |
Increase Decrease New since last portfolio | ||
Comgest Growth Europe EUR X Acc |